Press release content from Business Wire. The AP news staff was not involved in its creation.
Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial
February 11, 2021 GMT
Advanced Chemotherapy Technologies ACT-IOP-003 iontophoresis chemotherapy delivery system (Photo: Business Wire)
RALEIGH, N.C. (BUSINESS WIRE) Feb 10, 2021
Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Series A investment of $2.5 million with Spectrum Financial. This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture. The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.
E-Mail
IMAGE: UNC Lineberger Comprehensive Cancer Center s Jonathan S. Serody, MD, and colleagues report that adding a small molecule to a chimeric antigen receptor-T (CAR-T) cell therapy can help immune system T. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, NC Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more immune cells into battle at the tumor site. The findings are published in the